# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Deutsche Bank analyst George Hill maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target from $...
Barclays analyst Saket Kalia maintains Definitive Healthcare (NASDAQ:DH) with a Equal-Weight and lowers the price target fro...
Definitive Healthcare reports Q1 adjusted EPS of $0.08, sales at $63.48M, and adjusted EBITDA of $20 million. Q2 revenue guidan...
Canaccord Genuity analyst David Hynes maintains Definitive Healthcare (NASDAQ:DH) with a Hold and lowers the price target fr...
Stifel analyst David Grossman maintains Definitive Healthcare (NASDAQ:DH) with a Buy and lowers the price target from $11 to...
Needham analyst Ryan MacDonald reiterates Definitive Healthcare (NASDAQ:DH) with a Hold.